Mode
Text Size
Log in / Sign up
N/A N=33

The Effects of Spasticity on Glucose Metabolism in Individuals With Spinal Cord Injury

Spinal Cord Injuries

Enrolled (actual)
33
Serious AEs
0.0%
Results posted
Sep 2020
Primary outcome: Primary: Correlation Between Knee Flexor Muscle Modified Ashworth Scale and Insulin Resistance — -0.692; 0.23 correlation coefficient — p=0.006

Study Design & Population

Study type
Observational
Phase
N/A
Interventions
body composition (Diagnostic_test); glucose, insulin, glycohemoglobin (Diagnostic_test)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Fatih Sultan Mehmet Training and Research Hospital
Primary completion
May 2018

Outcome Measures

OutcomeResultp-value
PRIMARY
Correlation Between Knee Flexor Muscle Modified Ashworth Scale and Insulin Resistance
-0.692; 0.23 0.006 sig
PRIMARY
Correlation Between Knee Flexor Muscle Modified Ashworth Scale and Insulin Sensitivity
0.797; -0.084 0.001 sig
PRIMARY
Correlation Between Penn Spasm Frequency Scale and Insulin Resistance
0.354; -0.002 0.214
PRIMARY
Correlation Between Penn Spasm Frequency Scale and Insulin Sensitivity
0.289; -0.103 0.41
PRIMARY
Correlation Between Knee Flexor Muscle Modified Ashworth Scale and Total Body Fat-Free Mass%
0.201; 0.287 0.511
PRIMARY
Correlation Between Penn Spasm Frequency Scale and Total Body Fat-Free Mass%
-0.138; 0.526 0.654

Summary

Muscle atrophy may occur in individuals with spinal cord injury (SCI) as a result of diminished physical activity and alterations in glucose metabolism and body composition may be seen. In a few studies, it has been suggested that spasticity may have a positive impact on glucose metabolism by preventing muscle atrophy and alterations in body composition in individuals with motor complete SCI. Investigators aimed to assess the effects of spasticity on glucose metabolism and body composition in participants with complete and incomplete SCI.

Eligibility Criteria

Inclusion Criteria

  • Spinal cord injury AIS A,B,C,D

Exclusion Criteria

  • Other central nervous system diseases
  • Significant complications that affect spasticity
  • Joint contracture
  • Diabetes mellitus
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03859960). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search